Nanoparticle vaccine approach takes on a new target: Hepatitis C virus Scripps Research scientists reengineer critical proteins on the surface of HCV, paving the way for a new vaccine design.
March 03, 2026
LA JOLLA, CA Hepatitis C virus (HCV) infects an estimated 50 million people worldwide, according to the World Health Organization, and remains a leading cause of cirrhosis and liver cancer. While antiviral drugs can cure most infections, global access remains limited and these drugs do not stop reinfection.
This is why a durable vaccine is critically needed. Developing one has proven exceptionally challenging, however, as HCV evades immune detection using two distinct proteins that coat its surface. These proteins, known collectively as the E1E2 glycoprotein complex, have been historically difficult to produce in the stable, native form needed for vaccination.
In a new Nature Communications study, scientists at Scripps Research have now engineered that native-like, stabilized version of HCV's E1E2 complex and used it to build a nanoparticle-based vaccine candidate. The approach uses a technology called self-assembling protein nanoparticles, or SApNPs, which organizes many copies of the proteins into virus-like clusters that the immune system can more easily recognize. The study was published as an article-in-press on February 11, 2026.
Our lab focuses on all the major virus families, including those with surface proteins that are too unstable to use in traditional vaccines, says senior author Jiang Zhu, professor at Scripps Research. For HCV, the central problem for decades has been that the two surface proteins, E1 and E2, fall apart or misassemble when removed from the virus. In this study, we were able to stabilize the native E1 E2 interface and generate a soluble complex that faithfully mimics the viral surface.
On HCV's viral surface, E1 and E2 form tightly linked pairs known as heterodimers. Together, they both shield the virus from immune attack and allow it to attach to and enter human cells. Because vaccines train the immune system to recognize viral proteins, scientists must first recreate accurate copies of them in the lab. However, the E1 and E2 glycoproteins are notoriously difficult and labor-intensive to manufacture: once removed from the virus, they often misfold or fall apart.
For more than two decades, scientists been attempting to produce this stable, soluble E1E2 complex that preserves the correct interface between the two proteins. Without it, vaccines cannot teach the body's immune system to recognize HCV's true viral structure. It's remained a major unsolved challenge in the HCV field at large.
In the new study, Zhu and his team approached the challenge from a structural engineering perspective. They designed a molecular scaffold to hold E1 and E2 together in their native orientation, reinforcing key contact points that normally destabilize outside the viral membrane. The researchers then trimmed flexible regions that disrupted folding and added molecular connectors known as protein scaffolds to lock the pair into the correct alignment. Using various electron microscopy imaging techniques, they confirmed the engineered proteins preserved their native structure.
Normally, these glycoproteins are extremely fragile, Zhu adds. In the redesigned version, they became rock solid, while keeping the same shape the immune system requires to recognize them. That stability is essential because antibodies that neutralize HCV recognize a very specific arrangement of E1 and E2. If that interface isn't preserved, the vaccine won't present the right target.
Sixty copies of the stabilized proteins were then displayed on Zhu's proprietary SApNP technology. By clustering them together in this way, the particles mimic how viruses appear in nature and amplify the body's immune response. When tested in animal models, the HCV nanoparticle vaccine candidates triggered immune responses directed at the viral surface.
The soluble, stabilized E1E2 complex serves as the foundation for this multivalent display, potentially enabling a vaccine format that was previously not feasible, Zhu says.
Zhu's lab has spent years developing his nanoparticle-based platform for different vaccine targets. The approach relies on rational, structure-based design: researchers analyze viral surface proteins in fine detail, engineer stable versions and then mount them on virus-like protein particles to trigger a strong antibody response. Variations of the SApNP system have already been explored for multiple viruses, including HIV, influenza and most recently filoviruses like Ebola, Sudan, and Marburg.
HCV was one of the most challenging because it's a very difficult vaccine target, Zhu says. Our rational design approach allowed us to first identify why the virus' surface glycoproteins are so unstable, and then engineer solutions to overcome those challenges. Solving the soluble E1E2 problem removes a major bottleneck that has limited structure-based HCV vaccine design for decades.
Beyond a single vaccine candidate, Zhu echoes that the work shows promise in also benefitting the broader HCV field. Because the stabilized E1 and E2 proteins can now be produced reliably, they provide a template for researchers developing both vaccines and antibody-based therapies. It also opens new possibilities for structural studies and therapeutic antibody discovery.
For now, the team will refine the HCV vaccine candidates to strengthen immune responses and evaluate protection in future studies. Zhu is also working on solving another broader challenge in his vaccine design at large.
Over the last seven to eight years, I've been focused on solving protein designs for the major virus families, he says. Now, I'm also exploring strategies to further
Europe Stories
05/01/2027
Worlds first 802.15.4ab-UWB chip verified by Calterah and Rohde & Schwarz to be ...
01/06/2026
January 6 2026, 05:30 (PST) Dolby Sets the New Standard for Premium Entertainment at CES 2026
Throughout the week, Dolby brings to life the latest innovatio...
02/05/2026
Dalet, a leading technology and service provider for media-rich organizations, t...
01/05/2026
January 5 2026, 18:30 (PST) NBCUniversal's Peacock to Be First Streamer to ...
01/04/2026
January 4 2026, 18:00 (PST) DOLBY AND DOUYIN EMPOWER THE NEXT GENERATON OF CREATORS WITH DOLBY VISION
Douyin Users Can Now Create And Share Videos With Stun...
04/03/2026
For many fans, a song's backstory can be just as compelling as the final pro...
04/03/2026
In 2006, Spotify was founded on the belief that technology could bring artists a...
04/03/2026
Spotify is back on the ground for the Houston Livestock Show and Rodeo, and we&#...
04/03/2026
Spotify had an energizing week in Sydney, Australia, filled with powerful conver...
04/03/2026
Earlier this year, we launched Directed By, a documentary-style series that pull...
04/03/2026
KT and Rohde & Schwarz to showcase AI-enhanced radio transmission performance In a joint 6G AI proof-of-concept demonstration, the CMX500 one-box tester from ...
04/03/2026
Luxembourg, 3 March 2026 - SES S.A. has today published its 2025 Annual Report, following the announcement of the company's full year financial results for ...
04/03/2026
Luxembourg, March 3, 2026 - SES, a leading space solutions company, along with I...
04/03/2026
04 Mar 2026
VEON Partners with GSMA Innovation Fund to Accelerate Digital Innov...
04/03/2026
04 Mar 2026
VEON's Beeline Uzbekistan and Rakuten Symphony Partner for Open...
04/03/2026
Wednesday 4 March 2026
Sky Sports unveils plans for 2026 Formula 1 coverage
Sky Sports is preparing for one of the most highly anticipated F1 seasons in recen...
03/03/2026
For many, finding time or headspace to pick up a book can feel out of reach, but...
03/03/2026
Rohde & Schwarz and Realtek demonstrate first test solution for Bluetooth LE Hi...
03/03/2026
eds3_5_jq(document).ready(function($) { $(#eds_sliderM519).chameleonSlider_2_1({ content_source:......
03/03/2026
Luxembourg, 2 March 2026 -- SES S.A. fully consolidates Intelsat from 17 July 2025 and announces financial results for the year ended 31 December 2025
FY25 Pe...
03/03/2026
RT is proud to support a rich and diverse programme of arts and cultural events taking place across Ireland throughout March 2026. This month brings a remarkab...
03/03/2026
03 Mar 2026
VEON and MeetKai Expand Collaboration to Explore Sovereign AI Infra...
03/03/2026
Tuesday 3 March 2026
Sky releases official trailer for The Miniature Wife, a Sk...
03/03/2026
Tuesday 3 March 2026
Ryan Reynolds and Rob Mac land first ever live commentary ...
03/03/2026
Tuesday 3 March 2026
The Dyers' Caravan Park reopens for a second season after a hit launch on Sky
The Dyers' Caravan Park
JPEG (510KB)
Sky books a ...
03/03/2026
Harmonic's cOS Virtualized Broadband Platform Simplifies Network Operations, Lowers Hardware Dependency and Enables Seamless DOCSIS and Fiber Growth SAN JO...
03/03/2026
Comscore to Announce Fourth Quarter and Full Year 2025 Financial ResultsRESTON, VA, March 3, 2026 Comscore, Inc. (Nasdaq: SCOR), a trusted partner for plannin...
03/03/2026
Self-taught on iMovie, Hanagami transitioned to Final Cut Pro in 2009, discovering that professional tools could give him full creative control over how his wor...
03/03/2026
RT Media Sales has announced Spry Finance has renewed it's sponsorship of M...
02/03/2026
Rohde & Schwarz demonstrates FR1-FR3 carrier aggregation, advancing 6G readiness Rohde & Schwarz and Qualcomm Technologies, Inc. have reached another pivotal ...
02/03/2026
aconnic AG (ISIN: DE000A0LBKW6), Munich, and Arqit Quantum Inc. (Nasdaq: ARQQ, A...
02/03/2026
Luxembourg, February 26, 2026 - SES and Africa Mobile Network (AMN) have expande...
02/03/2026
Monday 2 March 2026
Saturday Night Live UK announces writing team
L-R: Jonno Johnson; Charlie Skelton; Celya AB; Omar Badawy; Gr inne Maguire; Laura Claxton; ...
27/02/2026
Since its inception, Gorillaz has been known for blending art with genre-bending...
27/02/2026
This week, Spotify introduced Audiobook Charts for the U.S. and U.K. The charts make it easy to discover your next favorite book by showing what's popular a...
27/02/2026
Rohde & Schwarz and Viasat to collaborate on NB-NTN IoT test plan for connectivi...
27/02/2026
In media technology, big features often steal the spotlight - AI integrations, cloud transformations, automation frameworks. But for the people who use these to...
27/02/2026
Digital Asset Management systems sit at the heart of most marcoms operations. They centralise content, organise it, and make it discoverable. Integrated with th...
27/02/2026
The AI Wild West comes to NAB 2026 and Blue Lucy is bringing the Sheriff
The AI Wild West is here, and media organisations are feeling the heat. On Booth W23...
27/02/2026
A deeply personal, uncompromising portrait of the legendary punk rock iconFriday...
27/02/2026
One of Ireland's favourite lifestyle shows Home of the Year, returns for its 12th series and will be proudly sponsored by SIRO. The brand-new series will ai...
27/02/2026
Our Farm: A GIY Story lands on RT One and RT Player from March 3
From walled garden to community farm, new six-part series captures the unfiltered realities...
27/02/2026
Note: English version included below the Irish language version.
Seachtain na Gaeilge 2026 ar RT
A Ghaeilge mo cheol th '
T feachtas athnuaite i n...
26/02/2026
Rohde & Schwarz awarded contract by Israel Airports Authority for QPS201 securit...
26/02/2026
Rohde & Schwarz highlights its unique CMX500 one-box tester tailored for NTN tes...
26/02/2026
Rohde & Schwarz high-efficiency transmitter powers next-gen broadcast services i...
26/02/2026
Rohde & Schwarz highlights its comprehensive embedded systems test solutions at ...
26/02/2026
Rohde & Schwarz to showcase spectrum security and network efficiency solutions a...
Nanoparticle vaccine approach takes on a new target: Hepatitis C virus Scripps Research scientists reengineer critical proteins on the surface of HCV, paving the way for a new vaccine design.
